rac-(1R,2S,5S)-3-[(tert-butoxy)carbonyl]-3-azabicyclo[3.2.0]heptane-2-carboxylic acid | 2248389-38-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: rac-(1R,2S,5S)-3-[(tert-butoxy)carbonyl]-3-azabicyclo[3.2.0]heptane-2-carboxylic acid
• 英文别名: (1S,2R,5R)-3-[(2-methylpropan-2-yl)oxycarbonyl]-3-azabicyclo[3.2.0]heptane-2-carboxylic acid
• CAS: 2248389-38-8
• 化学式: C₁₂H₁₉NO₄
• 分子量: 241.28
• InChiKey: RSDWKMNMYQDLJN-XHNCKOQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Immunoproteasome inhibitors
  申请人：Principia Biopharma Inc.

  公开号：US11154563B2

  公开（公告）日：2021-10-26

  Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本文提供的化合物，如本文所述的式(I)化合物或其药学上可接受的盐，是免疫蛋白酶体（如 LMP2 和 LMP7）抑制剂。本文所述化合物可用于治疗可通过抑制免疫蛋白酶体治疗的疾病。本文还提供了含有此类化合物的药物组合物和制备此类化合物的工艺。
• IMMUNOPROTEASOME INHIBITORS
  申请人：Principia Biopharma Inc.

  公开号：US20190336515A1

  公开（公告）日：2019-11-07

  Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
• [EN] INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉASES À CYSTÉINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：PARDES BIOSCIENCES INC

  公开号：WO2021212039A1

  公开（公告）日：2021-10-21

  The disclosure provides compounds with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.